Related Experiment Video
Updated: Feb 5, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
Key aspects of PCSK9 inhibition beyond LDL lowering
Purpose Of Review:
Our primary objective is to review the most recent findings on the biology of PCSK9 and on two key aspects of PCSK9 inhibition beyond LDL control of great clinical relevance: the regulation of lipoprotein (a) circulating levels by PCSK9 inhibitors and the putative diabetogenic effects of these novel therapies.
Recent Findings:
The reality of two distinct extracellular and intracellular pathways by which PCSK9 decreases the abundance of the LDLR at the surface of many cell types, most importantly hepatocytes, has recently been established. In contrast, the exact mechanisms by which PCSK9 inhibitors lower the circulating levels of lipoprotein (a) remain a point of major dispute. Despite strong indications from genetic studies that PCSK9 inhibition should increase diabetes risk, no such effect has been observed in clinical trials, and in-vitro and in-vivo studies do not clarify this issue.
Summary:
The trafficking pathways by which PCSK9 enhance LDLR degradation via the endolysosomal extracellular route or via the Golgi-lysosomal intracellular route remain to be fully elucidated. The mechanisms by which PCSK9 inhibitors reduce lipoprotein (a) also merit additional research efforts. The role of PCSK9 on glucose metabolism should likewise be studied in depth.
Insights
Recent reviews explore proprotein convertase subtilisin/kexin type 9 (PCSK9) biology and its inhibitors. Key areas include lipoprotein (a) regulation and potential diabetes risks, with ongoing research into mechanisms.
Area of Science:
- Biochemistry
- Cardiovascular Medicine
- Pharmacology
Background:
- Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a critical role in regulating low-density lipoprotein receptor (LDLR) abundance.
- PCSK9 influences lipid metabolism through distinct intracellular and extracellular pathways affecting LDLR degradation.
Purpose of the Study:
- To review current knowledge on PCSK9 biology and inhibition.
- To examine PCSK9 inhibitors' effects on lipoprotein (a) levels.
- To assess the potential diabetogenic effects of PCSK9 inhibition.
Main Methods:
- Literature review of recent findings on PCSK9 biology.
- Analysis of studies on PCSK9 inhibitors' impact on lipoprotein (a).
- Evaluation of clinical trial and experimental data regarding PCSK9 inhibition and diabetes risk.
Main Results:
- Two pathways for PCSK9-mediated LDLR degradation (extracellular and intracellular) are established.
- Mechanisms by which PCSK9 inhibitors lower lipoprotein (a) remain debated.
- Clinical trials have not shown an increased diabetes risk with PCSK9 inhibition, contrary to genetic predictions.
Conclusions:
- Further research is needed to fully elucidate PCSK9 trafficking pathways and LDLR degradation.
- Additional studies are required to clarify the mechanisms of PCSK9 inhibition on lipoprotein (a) levels.
- The precise role of PCSK9 in glucose metabolism warrants in-depth investigation.
Related Concept Videos
Vapor Pressure Lowering
Feedback Inhibition
Key Techniques in Microbiology
Key Elements for Plant Nutrition
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Quantitative Aspects of Drug-Receptor Interaction

